Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety
16. Juni 2015 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
11. Juni 2015 08:50 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 11, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces Presentation at the Jefferies 2015 Healthcare Conference
27. Mai 2015 17:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH)
26. Mai 2015 07:09 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 26, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
Aegerion Pharmaceuticals Announces Resignation of Chief Financial Officer
14. Mai 2015 17:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
11. Mai 2015 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results
04. Mai 2015 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
- Company records $59.4 million in total net product sales -
- JUXTAPID® net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first quarter of 2014...
Aegerion Pharmaceuticals to Present at Upcoming Investor Conferences
04. Mai 2015 07:55 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 4, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals to Announce First Quarter 2015 Financial Results on Monday, May 4
21. April 2015 16:15 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
14. April 2015 17:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...